My primary research goal is to define evolutionary dependencies in drug resistance. Using multiplexed proteomic and genomic measurements, high-throughput microscopy, single-cell analysis, and multi-scale modeling, at a single-cell level, I am delineating molecular mechanisms that underlie adaptive cell fate decisions in the presence of cell-autonomous, microenvironment, and therapy-induced selective pressures, and elucidate how they vary in cancer drug resistance. With learning of evolutionary dependencies using a detailed and network-level understanding, we provide a rational basis for choosing the optimal molecular targets to: (i) maximize therapeutic response, (ii) prevent therapeutic resistance, and (iii) reduce therapy-induced adverse effects.

Deep Expertise: Protein-protein interaction, Therapeutic Resistance, RNA-seq, single cell genomic and proteomic techniques and cancer metastasis.

Shah KN, Bandyopadhyay S. Targeting the evolution of drug resistance in lung cancer, Molecular and cellular oncology Available online May 23^rd, 2019 

Shah KN, Bhatt R,Rotow J, Rohrberg J , Olivas V, Wang VE,Hemmati G,  Martins MM,Maynard M, Kuhn J, Galeas J, Donnella H,Kaushik S,  Ku A,Dumont S, Krings G, Haringsma HJ, Robillard L,Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Aurorakinase A drives the evolution of resistance to third generation EGFR inhibitorsin lung cancer Nat Med. 2019; 25(1):111-118

Donnella HJ, Webber JT, Camarda R, Momcilovic O, Bayani R, Shah KN,Shokat KM, Goga A, Gordon JD, Bandyopadhyay S. Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer, Nature Chemical Biology 14 (8), 768: 2018

Hu HM, Shah KN, Bandyopadhyay S et.al. A quantitative chemotherapygenetic interaction map reveals factors associated with PARP inhibitor resistance. Cell reports 23 (3),918-929: 2018

Shah KN, Faridi JS et.al, Targeting RRM2 and NF-κB activation with didox to circumvent tamoxifen resistance in breast cancer. Mol Cancer Ther.2015; 14(11): 2411-21

Shah KN, Mehta K, Peterson D, Evangelista,M, Livesey J, Faridi JS, Akt-Induced tamoxifen resistance is reversed by RRM2 inhibition, Mol Cancer Res.2014; 12(3): 394-407

Shah KN, Faridi JS, Estrogen, tamoxifen, and Akt modulate expression of putative house-keeping genes in breast cancer cells.J Steroid Biochem Mol Biol.2011; 125(3-5): 219-25